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ABSTRACT 
FHA (forkhead-associated) domains are modular phosphopeptide recognition motifs with a 
striking preference for phosphothreonine-containing epitopes. FHA domains have been best 
characterised in eukaryotic signalling pathways but have been identified in six proteins in 
Mycobacterium tuberculosis, the causative organism of tuberculosis. One of these, coded by gene 
Rv1747, is an ABC transporter and the only one to contain two such modules. A deletion mutant 
of Rv1747 is attenuated in a mouse intravenous injection model of tuberculosis where the 
bacterial load of the mutant is ten-fold lower than that of the wild type in both lungs and spleen. 
In addition, growth of the mutant in mouse bone marrow-derived macrophages and dendritic cells 
is significantly impaired. In contrast, growth of this mutant in vitro was indistinguishable from 
that of the wild type. The mutant phenotype was lost when the mutation was complemented by 
the wild type allele, confirming that it was due to mutation of Rv1747. Using yeast two-hybrid 
analysis, we have shown that the Rv1747 protein interacts with the serine-threonine protein 
kinase PknF. This interaction appears to be phospho-dependent since it is abrogated in a kinase-
dead mutant and by mutations in the presumed activation loop of PknF and in the first FHA 
domain of Rv1747. These results demonstrate that the protein coded by Rv1747 is required for 
normal virulent infection by M. tuberculosis in mice, and, since it interacts with a serine-
threonine protein kinase in a kinase-dependent manner, indicate that it forms part of an important 
phospho-dependent signalling pathway. 
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INTRODUCTION 
 
Tuberculosis (TB) was declared a global emergency by the World Health Organisation in 1993. 
Despite this, estimates suggested that 8.2 million new cases were still occurring world-wide in the 
year 2000, with 2-3 million people dying from the disease, and a third of the world’s population 
are infected (39). There has been enormous progress in combating the disease including the 
publication of the complete genome of its causative agent, the bacterium Mycobacterium 
tuberculosis (7). However, the situation has deteriorated in a number of regions due to synergy 
between TB and AIDS (21). The only vaccine for TB, Mycobacterium bovis BCG, developed in 
the 1920s, does not provide adequate levels of protection in Africa, India and some parts of the 
USA (12, 13). Moreover, the rise in multi-drug resistant tuberculosis makes the identification of 
new drug targets and vaccines imperative (39). 
 The identification of virulence determinants is one approach to the development of novel 
disease intervention strategies that could be used to develop new therapeutic agents or attenuated 
vaccine strains. One likely class of proteins for the search for such virulence determinants is in 
regulatory proteins (eg. 27, 35, 38, 40). In particular, protein kinases have, perhaps surprisingly, 
emerged as major targets for pharmaceutical intervention over the last few years. Mycobacterium 
tuberculosis  faces complex environmental and metabolic choices as it moves from the 
environment to infection of macrophages, dormancy and growth in the host.  It is therefore 
expected to have an extensive repertoire of regulatory proteins with over 100 predicted in the 
genome (7).  Phosphorylation on serine, threonine or tyrosine is the most common post-
translational modification utilised in cellular signalling processes in eukaryotes where the 
interplay of protein kinases and phosphatases provides for rapid reversibility. In prokaryotes, 
phosphorylation-dependent signalling is manifested in the use of so-called two-component 
systems where phosphate is transferred from a histidine on a sensor kinase to a glutamate or 
aspartate on a response regulator. M. tuberculosis has only eleven two-component networks  
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compared with Bacillus subtilis and Escherichia coli which each contain over thirty. 
Nevertheless, it does contain eleven putative Ser-Thr protein kinases. Interestingly, four of these 
genes are linked in the genome to genes coding for proteins that have the forkhead-associated 
(FHA) domain that fulfils the important role of modular phosphothreonine binding motif (48). 
Indeed, the presence of a FHA domain is now generally taken to indicate that the protein is likely 
to interact with a phosphorylated protein partner (10) although such interactions have been 
demonstrated in only a relatively limited cohort of biological systems.  
The  M. tuberculosis gene Rv1747 encodes a 92 kDa protein containing an ABC 
transporter domain and two FHA domains. Although its function is unknown it has been 
suggested that it functions as an exporter (5). It is one of two genes in a putative operon (7) where 
the first encodes a eukaryotic-like serine/threonine protein kinase, Rv1746 (pknF) (See Fig. 1). 
Taken together, these observations suggest that Rv1747 is not only likely to function as an 
exporter with potential importance in virulence, but that it may be part of a complex signalling 
system involving a eukaryotic-like STK pathway. Here we have investigated the role of Rv1747 
in microbial pathogenesis and further examined the potential for regulatory interactions between 
the FHA domains of Rv1747 and PknF. 
 
MATERIALS AND METHODS 
  Strains, growth conditions, and reagents.  The wild type strain used was Mycobacterium 
tuberculosis H37Rv Paris (kindly provided by S. Cole). All strains were grown at 37°C in Dubos 
broth supplemented with 0.05% (v/v) Tween 80, 0.2% (v/v) glycerol and 4% (v/v) Dubos 
medium albumin (Becton Dickinson), either 100 ml in a Bellco roll-in incubator (2 r.p.m.) or 10 
ml in static universals. Mutant strains of M. tuberculosis were plated onto Middlebrook 7H11 
agar supplemented with 4% (v/v) Dubos medium albumin, and, as noted, with hygromycin (100 
µg ml
-1), kanamycin (25 µg ml
-1), X-Gal (50 µg ml
-1), or sucrose (2% w/v). The PCR products  
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were cloned using the Zero Blunt TOPO PCR cloning kit (Invitrogen). Adult (8 week) female 
Balb/C mice were obtained from the specific pathogen free animal unit at NIMR. 
  Isolation of nucleic acids from mycobacteria.  Extraction of genomic DNA used a 
modification of the method of Belisle et al. (3), adapted from Whipple et al. (47). For RNA 
extraction, rolling cultures of M. tuberculosis were harvested by centrifugation, and RNA 
extracted by mechanical lysis using the Fast RNA Pro Blue kit (Q-BIOgene-ALEXIS). The RNA 
had DNA removed by DNase digestion. 
 Sequence  analysis.  Sequencing was carried out using the BigDye Terminator Cycle 
Sequencing kit on an ABI
 Prism 377 DNA analyzer, both from Applied Biosystems. The results 
were compared with the published M. tuberculosis sequence (7) using the BLAST facility on the 
website http://genolist.pasteur.fr/TubercuList/. Sequencing to check the constructs for the Rv1747 
knockout was carried out using primers 5'-TTTGCACCTCGCGTTCT-3' and 5'-
ACCAACACCACCATCTG-3' for the BamHI insert, and primers 5'-
GTGATGCTGTCGAGCTT-3' and 5'-TTGAGCACCTTGTGTGT-3' for the NotI insert. The 
complement was also sequenced entirely. 
 Microarrays.  Microarrays of the M. tuberculosis genome were obtained from Dr. J. Hinds 
and Prof. P. Butcher, Bacterial Microarray Group, St. Georges Hospital Medical School, London. 
The arrays were scanned using an Axon 4000A together with GenePix software. 
  Construction of Rv1747 null mutant. Plasmid constructs were made by inserting 2 kb 
regions of amplified H37Rv Paris DNA flanking each side of the knockout gene into the vector 
p2NIL (36) (See Fig. 1). The primers for the flanking regions were:  5'-GGATCC-
GTAACATCGCGCACGAATTG-3' and 5'-GGATCC-CAGCCGTTGCTTCTGCGAAT-3' 
(BamHI insert), and 5'-GCGGCCGC-GTGACGTGCGACTGATTCTG-3' and 5'-GCGGCCGC-
TTGCGAGCAGGTGACACCTT-3' (NotI insert), both amplified with the enzyme Elongase 
(Promega). The hyg cassette was cut from pUC-HY vector (26, 41) using KpnI and inserted  
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between the 5’ and 3’ flanking regions. Finally, the sacB gene and the lacZ gene were inserted 
from the plasmid pGOAL17 (36) using PacI. The plasmid constructs were pretreated with 100 mJ 
UV light cm
-2 (19) and used to electroporate M. tuberculosis (34). This was plated onto 7H11 
plates supplemented with X-Gal, kanamycin and hygromycin and left to grow for 3 weeks. Single 
crossover events, seen as blue colonies, were streaked onto 7H11 supplemented with hygromycin 
and grown for a further 3 weeks before serially diluting and streaking onto 7H11 supplemented 
with sucrose and hygromycin. The resulting colonies were patch tested on 7H11 plates containing 
hygromycin, with X-Gal or kanamycin, to check for white, kanamycin-sensitive colonies, 
indicating a double crossover event. 
  Check of Rv1747 null mutant. The Rv1747 null mutant was checked by PCR, Southern blot 
and genomic DNA microarray to ensure the gene had been knocked out. For PCR, the following 
primer pairs were used: 5'-GCGTTGACCTGCGTGTT-3' from M. tuberculosis 5' of the BamHI 
insert and 5'-CGTTCGAACGCGGCTAC-3' from the p2NIL multiple cloning site; 5'-
GGTCAGCGAACCAATCA-3' from the p2NIL multiple cloning site and 5'-
ACAGGACACCTGCTATG-3' from M. tuberculosis 3' of the NotI insert. The fragments were 
amplified with an annealing temperature of 55ºC using Hotstar Taq. For Southern blots genomic 
DNA was digested with the restriction enzyme AscI, and blots were probed with DNA from 
outside the knock-out construct, one from pknE (derived by PCR using the primers 5’-GGATCC-
TTCAACGAACCCATCTGTCC-3’ and  5’-TCGAATAGTTCTTGCTG-3’) and the other from 
Rv1750c (fad1) (derived using primers 5-CATAGCAGGTGTCCTGTT-3’ and  5’-
GGCTGAATTGGTGGCTG-3’). An AscI site is lost when the Rv1747 gene was deleted so that 
an approx. 7kb fragment that hybridized with the pknE probe and an approx. 10kb fragment that 
hybridized with the fad1 probe were replaced by an approx. 15kb fragment (data not shown). 
Genomic DNA was isolated and used to probe M. tuberculosis DNA microarrays as described 
previously (14).  
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  Complementation of the Rv1747 mutation. The genes Rv1747, Rv1746 and 609 bp of 
Rv1745 (See Fig. 1) were amplified by PCR using the primers 5'-AAGCTT-
GCACGCCTTGAGGCGAATCT-3' (5’ HindIII restriction site) and 5'-GAATTC-
GTAACATCGCGCACGAATTG-3' (5’ EcoRI restriction site) and the Expand Long Template 
PCR system. The PCR product was sequenced to check there were no base changes. After 
restriction enzyme digestion, the PCR product was then cloned into the integrating vector 
pMV306 (43) and used to electroporate the M. tuberculosis Rv1747 knockout. This was plated 
onto 7H11 plates supplemented with kanamycin and hygromycin and left to grow for 3 weeks. 
The resulting colonies were harvested, the DNA extracted, and checked for complementation by 
PCR and microarrays. 
 In  vitro growth determination. Wild type H37Rv Paris and the Rv1747 knockout mutant and 
its complement strain were each initially removed from storage at -80°C, grown in 10 ml Dubos 
medium as static cultures, and then at 37ºC in a rolling incubator as described above. Once they 
each reached an OD600 of approximately 0.5, 1 ml of each culture was subcultured to a fresh 
bottle of 100 ml Dubos medium and incubation continued in the rolling incubator. Aliquots of 1 
ml of each culture were removed for optical density readings at 600 nm at 24 h intervals. 
  Growth of bacteria in mice. Stock cultures of M. tuberculosis H37Rv Paris, Rv1747 
knockout and Rv1747 complement were grown in 10 ml Dubos medium standing cultures at 37ºC 
for 14 days. The cultures were diluted in phosphate-buffered saline to an OD600 of 0.02. Infection 
was induced by injecting 0.2 ml viable M. tuberculosis (5 x 10
5 CFUs) into a lateral tail vein of 8 
week old adult female Balb/C mice. The infection was monitored by removing the lungs and 
spleens of infected mice at various intervals, homogenising the tissues and plating 10-fold 
dilutions to determine numbers of colony forming units of M. tuberculosis (45). The growth 
curves were compared by graph and statistical analysis. The results for each time point are the 
means of CFU determinations performed on organs from three mice, and the error bars show the 
standard deviations. The asterisk indicates that the result is statistically significantly different  
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from that of the wild type by the two-tailed Student’s t test for groups of unequal variance (p < 
0.01), as well as by single-factor analysis of variance (p < 0.01). 
  Growth of bacteria in mouse cell culture. Bone marrow cells were extracted from the hind 
legs of 8 week old adult female Balb/C mice as described previously (44). The cells were 
resuspended in IMDM+5% FCS, 2mM L-glutamine, 80uM β-mercaptoethanol to which was 
added, for macrophages, 10% by volume of supernatant from L929 cells that produce M-CSF, or 
for dendritic cells, 10% supernatant from X-63 cells transfected with GM-CSF cDNA.  The cells 
were plated in 6 well plates and incubated at 37ºC and 5% CO2 atmosphere for 24 h.  At day 2 the 
cells were washed with fresh pre-warmed medium, and non-adherent dendritic cells were plated 
in new 6 well plates.  Fresh medium was added to the plates containing the adherent bone marrow 
macrophage cells. The cells were cultured for a further 3 days and at day 5 they were infected for 
6 h at a ratio of 2:1 cells:acid fast bacilli. After infection the medium was removed and replaced 
with fresh medium. The bone marrow macrophages and dendritic cells were lysed with 2% 
saponin and incubated for 1 h at 37°C. Growth was determined by viable counts on Middlebrook 
7H11 agar plates containing Middlebrook OADC supplement at days 0 (6 h post-infection), 4, 7 
and 11 post-infection. The growth curves were compared by graph and statistical analysis. The 
results for each time point are the means of CFU determinations from at least 3 wells, and the 
error bars show the standard deviations. The asterisk indicates that the result is statistically 
significantly different from that of the wild type by the two-tailed Student’s t test for groups of 
unequal variance (p < 0.02), as well as by single-factor analysis of variance (p < 0.02). 
Yeast two-hybrid analysis. The pknF and Rv1747 genes were amplified by PCR using 
the proofreading polymerase Pfu turbo (Stratagene), and template chromosomal DNA from M. 
tuberculosis H37Rv. For pknF the amplification primers were: 5’-CTGCAG-
CATGCCGCTCGCGGAAGGTT-3’ (forward primer) and 5’-CTGCAG-
CGGCCAGCCGTTGCTTCTGC-3’ (reverse primer) both carrying a PstI site at the 5’ end. For 
Rv1747 the primers were: 5’-GGATCC-GTGCCGATGAGCCAACCAGC-3’ and 5’-GGATCC- 
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GCACGCCTTGAGGCGAATCT-3’ both carrying a 5’BamHI site. The restriction sites were 
used to clone the genes into the yeast two-hybrid Gal4 activation domain vectors pGAD-C3 and 
pGAD-C1 respectively, and the Gal4 binding domain vectors pGBD-C3 and pGBD-C1 
respectively (22). Constructs were confirmed by sequencing. Saccharomyces cerevisiae Y187 
(MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, gal4∆, met
–, gal80∆, URA3 : : 
GAL1UAS -GAL1TATA –lacZ) (17) were co-transformed  with Gal4 activation domain and Gal4 
binding domain vectors according to the LiAc TRAFO method (16), and plated onto minimal 
Difco plates lacking Leu and Trp for selection of transformants. Protein interactions were 
measured by assaying for lacZ expression using o-nitrophenyl-β-D-galactopyranoside (ONPG) as 
substrate (28) and expressed as units/min./mg. protein. All pknF and Rv1747 Gal4 constructs 
were co-transformed with either empty pGAD or pGBD vectors to eliminate false positives. 
  Site directed mutagenesis. Site directed mutagenesis was carried out according to the 
Stratagene QuickChange
 XL Site-Directed Mutagenesis manual, using SoloPack Gold 
Supercompetent E. coli for transformation. Primers used for mutagenesis are described in Table 
1. A mutation was introduced into the PknF active site, where Lys-41 was substituted by Ala. 
Mutation of the activation loop of PknF was created by individual substitution of Thr-173, -175 
and -178 with alanines. Rv1747 was mutated in FHA domain-1, where Ser-47 was substituted by 
Ala, and a second mutant was created where Ser-248 in FHA domain-2 was also substituted by 
Ala. The presence of the desired mutations was confirmed by sequencing. 
 
RESULTS 
  Construction of a Rv1747 knockout. The serine-threonine protein kinase pknF is adjacent to 
and probably in the same operon as Rv1747, an ABC transporter protein with two forkhead-
associated domains (Fig. 1). Most of the coding region of gene Rv1747 was successfully deleted 
from M. tuberculosis H37Rv using homologous recombination, and this was confirmed by PCR, 
Southern blot and DNA microarray (see Materials and Methods). A complement strain was  
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constructed using the region of DNA including the promoter, Rv1746 and Rv1747 to demonstrate 
that phenotypic effects were due to deletion of Rv1747 and not to downstream polar effects of the 
mutation on Rv1748. Microarray experiments using DNA from the complement strain showed 
that the Rv1747 gene had indeed been replaced and that there was an additional Rv1746 gene 
(data not shown). 
  Growth of the Rv1747 mutant is normal in vitro but attenuated in vivo. Growth, as 
measured by optical density readings at 600 nm, of the Rv1747 mutant and its complement 
compared to growth of the H37Rv wild type in 100 ml Dubos rolling culture was not statistically 
different (Fig. 2). However, mouse infection with the Rv1747 mutant resulted in severely 
impaired growth of the mutant compared with the wild type H37Rv. This was demonstrated in 
both the lungs (by t-test, p = 6.4 x 10
-4) and spleen (p = 3.5 x 10
-4) of mice (Fig. 3). The mutant 
was also significantly different to the complement (p = 1.4 x 10
-3 and 4.4 x 10
-5 in lungs and 
spleen respectively). The mutant strain did however persist within the animals. In mouse bone 
marrow-derived macrophages growth of the Rv1747 knockout was impaired compared to both 
the H37Rv wild type and Rv1747 complement by t-test (Fig. 4, p = 4.5 x 10
-4 and 3.9 x 10
-4 
respectively). In bone marrow-derived dendritic cells the Rv1747 complement did not grow as 
well as the H37Rv wild type but the difference was not significantly different (see Fig. 4), 
whereas the Rv1747 mutant was again significantly impaired in growth compared to the H37Rv 
wild type by t-test (p = 0.019). The mutant was also significantly different to the complement (p = 
0.034). 
  Interaction between PknF and Rv1747 is phospho- and FHA domain-dependent. Using 
yeast two-hybrid analysis, a strong interaction was observed between PknF and Rv1747 (Fig. 5, 
bar 5). This interaction was abolished upon mutation of Lys-41 to Ala in the active site of PknF 
(23) (Fig. 5, bar 8) strongly suggesting that the interaction between PknF and Rv1747 is 
phosphorylation-dependent.   
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  Interaction of PknF with Rv1747 was abolished by mutation to Ala of Thr-173 in the 
activation loop of PknF (Fig. 5, bar 9). Mutation of Thr-175 or Thr-178 (Fig. 5, bars 10 and 11) 
reduced the interaction by less than 3-fold, showing that all three threonines are involved in the 
interaction, but that only Thr-173 is essential for recognition by the FHA-containing Rv1747.  
  The X-ray structure of FHA1 of Rad53p in complex with a phospho-threonine peptide has 
indicated that there are six highly conserved residues in the FHA domain (11). Five are located 
around the peptide binding site, three of which make interactions with the peptide. Of these three, 
only two, Arg-70 and Ser-85, bind directly to the pThr residue itself (Fig. 6). We have therefore 
mutated the equivalent serine residues in the two FHA domains of Rv1747, Ser-47 in FHA-1 and 
Ser-248 in FHA-2. The interaction of Rv1747 with PknF was reduced by greater than 99% by 
substitution of Ser-47 by Ala in FHA domain 1 of Rv1747 (Fig. 5, bar 6), and was reduced by 
~60% by the mutation of Ser-248 to Ala in FHA-2 (Fig. 5, bar 7), suggesting that both FHA 
domains are involved in the interaction with PknF, but only FHA-1 is essential for this process. 
These data complement and extend previous observations that the level of phosphorylation of 
Rv1747 by PknF is dependent on both FHA domains (31). A weak but measurable interaction 
was noted when Rv1747 was present in both the activation and binding domains of Gal4 showing 
that this protein interacts with itself (Fig. 5, bar 4). This is consistent with the fact that ABC 
transporters are generally active as dimers or higher oligomers. Nevertheless, this weak 
interaction was not affected by either of the mutations in the Rv1747 FHA domains (data not 
shown). 
DISCUSSION 
Reversible phosphorylation is a ubiquitous mechanism of signalling transduction. In 
eukaryotes, proteins are phosphorylated on either tyrosine residues or serine/threonine residues by 
two distinct but structurally related families of kinases. In contrast, prokaryotes utilise the 
phosphorylation of histidine residues and subsequent phosphoryl transfer to aspartate residues in 
so-called two-component phosphorelay systems. Somewhat surprisingly, the genome sequence of  
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M. tuberculosis revealed a number of putative two-component histidine kinases but also a 
complement of 11 eukaryotic-like serine-threonine kinases together with a number of 
phosphatases (7). It has been postulated that these kinases are likely to play regulatory roles (1) 
and some of them have been investigated biochemically (2, 23, 29, 30, 37) and structurally (32, 
49). Potential regulatory functions have been have been investigated in some cases (for review 
see 33). For example, PknA has been implicated in the regulation of morphological changes 
associated with cell division (6), PknH is differentially expressed under stress conditions (42) and 
PknG is linked to cellular glutamate levels (8) and is secreted within macrophages and inhibits 
phagosome-lysosome fusion (46). Inactivation of PknG led to lysosomal localization and 
mycobacterial cell death due to loss of inhibition of phagosome-lysosome fusion (46). 
The FHA domain is a modular phosphopeptide recognition motif (9) showing a striking 
specificity for phosphothreonine-containing epitopes (11). FHA domains have been best studied 
in their roles in the eukaryotic DNA damage response, in particular, in the context of the 
Rad53/Chk2 family of checkpoint kinases. Of particular relevance is the observation that these 
molecules encode modular proteins each containing an STK domain together with one or more 
FHA domains. In this context, the FHA domains seem to play a variety of regulatory roles in 
kinase activation and subcellular localisation. However, relatively little is known about how 
prokaryotic FHA domains function. Notably, four M. tuberculosis STK-encoding genes are 
linked to genes coding for proteins containing the FHA phosphopeptide recognition domain 
suggesting, by analogy to Chk2 and Rad53, that they may play a direct role in regulating STK 
activity. Support for this notion has emerged from studies of PknH which been shown to 
phosphorylate the FHA-containing EmbR protein, an activity that is abolished by mutations in the 
FHA domain of EmbR that would be predicted to compromise pThr-binding (30). 
In the present study we have demonstrated the interaction of PknF with the product of 
Rv1747. We have corroborated this result by mutating both the PknF kinase and Rv1747. Thus, 
this interaction was abrogated by mutation of Lys-41, known to abolish the kinase activity of  
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PknF (23), providing evidence that the interaction between PknF and Rv1747 is phosphorylation 
dependent. It was also abolished by mutation of Thr-173 in the activation loop of PknF, but 
reduced only 3-fold by mutation of Thr-175 or Thr-178. Thr-173 and -175 are homologous with 
residues Thr-171 and Thr-173 in PknB, identified as autophosphorylation sites in PknB (4). The 
presence of pThr in FHA domain binding sites has been shown to be essential for interaction (11) 
suggesting that Thr-173 may be the phosphorylation site of PknF that is recognised by the 
Rv1747 FHA domains. Alternatively, since mutation of Thr-173 in the activation loop could, 
potentially, prevent auto-phosphorylation at other sites in PknF, confident assignment of the 
actual FHA binding site will require further investigation and these experiments are in progress. 
Lastly, the protein-protein interaction was disrupted by mutation of Ser-47 of Rv1747, which is 
highly conserved in FHA domains and directly interacts with the phosphothreonine residue in 
both Rad53 FHA-1 and the FHA domain of Chk2 (11, 24). In contrast, binding was reduced by 
less than 3-fold upon mutation of Ser-248 in the second putative FHA domain. These results 
suggest that phospho-dependent interactions between PknF and the FHA domain of Rv1747 form 
part of a regulatory cascade that involves phosphorylation by PknF that is directed predominantly 
by binding of FHA-1 to a pThr-containing autophosphorylation site on PknF, possibly located 
within the kinase activation loop itself. 
  Rv1747 codes for an ABC-transporter protein. ATP binding cassette (ABC) transport 
systems occur in all cells of all living species (18) and in M. tuberculosis genes encoding these 
proteins occupy 2.5% of the genome (5). They are involved in the active transport of solutes 
across cellular membranes, including the uptake of a large variety of essential nutrients and the 
secretion of virulence factors, proteases and toxins. The ABC transporter gene Rv1747 contains 
only one membrane spanning domain and one nucleotide binding domain so is expected to 
dimerise to function as a transporter (5). There is presently no information as to what substrate it 
transports. Similarity has been found with the White protein from Drosophila melanogaster, a 
permease necessary for the transport of pigment precursors into pigment cells responsible for eye  
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colour, and with NodI from Rhizobium and Bradyrhizobium strains, a protein implicated in the 
nodulation process by the export of a polysaccharide (5). It has been suggested that the substance 
transported may be a lipooligosaccharide (http://genolist.pasteur.fr/TubercuList/)  and that the 
Rv1747 product possibly functions as an exporter protein (5). Among eukaryotic ABC 
transporters with known structures, Rv1747 is most closely related at the sequence level to TAP 
(transporter associated with antigen processing; PDB ID 1JJ7, E=7e-15) (25) and CTFR (cystic 
fibrosis transmembrane conductance channel; PDB ID 1R10, E=4e-10) (15), which are both 
regulated by phosphorylation. 
The phenotype of the Rv1747 knockout demonstrated here is the first reported mutation 
in an FHA domain-containing protein of M. tuberculosis, and is intriguing in its very marked 
reduction in growth in macrophages and in mice. Thus the mutant exhibited greatly reduced 
bacterial loads in the mouse lungs and spleen compared with infection by the wild-type and 
therefore falls within the growth in vivo (giv) type of mutant defined by Hingley-Wilson et al. 
(20). This ABC transporter system therefore appears to be very important for the normal growth 
of the bacterium during the multiplication phase in macrophages and in mice, but did not appear 
necessary for the persistence phase of growth. Clearly, whether the protein involved is importing 
or exporting a substrate, its absence results in failure of the mycobacterium to thrive in mice but 
makes no difference to its growth in vitro. The fact that Rv1747 interacts with the PknF kinase 
suggests that its activity is modulated in response to unknown signals that are potentially detected 
by pknF through its extracellular C-terminal region/domain and transduced into the intracellular 
milieu via the activity of its STK domain. 
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FIGURE LEGENDS 
FIG. 1. Diagram of the genomic region of M. tuberculosis containing the pknF and Rv1747 
operon and adjacent genes, showing the extent of the deletion and the complementing plasmid 
pRv1747
+. The marks on the chromosome are at 1000 bp intervals. 
FIG. 2. Growth of the Rv1747 knock-out mutant is unimpaired in vitro. The H37Rv wild-type, 
Rv1747 knock-out and the complemented strain were grown in Dubos medium in rolling bottles 
as described in Materials and Methods, and optical density measurements were made on 1 ml 
aliquots taken at 24 hour intervals. There was no statistical difference between the OD 
measurements from the three strains. 
FIG. 3. Growth of the Rv1747 knock-out mutant is impaired in a mouse intravenous infection. 
BALB/c mice were inoculated intravenously with approximately 5 x 10
5 CFU of each strain. The 
survival and multiplication of the M. tuberculosis strains in the lungs and the spleen were 
determined by CFU counts and are shown for the H37Rv wild-type (●), Rv1747 knockout mutant 
(○), and Rv1747 complemented mutant (▼) strains. The results for each time point are the means 
of CFU determinations performed on organs from 3 to 5 infected mice, and error bars indicate the 
standard deviations. The asterisks indicates that the result is statistically significantly different 
from that of the wild type by the two-tailed Student’s t test for groups of unequal variance (p < 
0.01), as well as by single-factor analysis of variance (p < 0.01). 
FIG. 4. Growth of the Rv1747 knock-out mutant is impaired in in vitro infections into mouse 
bone marrow-derived macrophages and dendritic cells. Macrophages were isolated from BALB/c 
mice as described in the text and infected at a multiplicity of infection of one bacterium to two 
macrophages with each strain. The survival and multiplication of the M. tuberculosis strains were 
determined by CFU counts and are shown for the H37Rv wild-type (●), Rv1747 knockout mutant 
(○), and Rv1747 complemented mutant (▼) strains. The experiment was performed twice with 
similar results; the results of a representative experiment are shown. The results for each time  
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point are the means of CFU determinations performed on triplicate infections, and error bars 
indicate the standard deviations. The asterisks indicates that the result is statistically significantly 
different from that of the wild type by the two-tailed Student’s t test for groups of unequal 
variance (p < 0.02), as well as by single-factor analysis of variance (p < 0.02). 
FIG. 5. β-galactosidase assay of yeast two-hybrid constructs showing the effect of the PknF 
K41A, T173A, T175A and T178A mutations, and the Rv1747 S47A and S248A mutations, on 
the interaction between PknF and Rv1747. S. cerevisiae Y187 were co-transformed with plasmids 
expressing PknF in the Gal4 binding domain and Rv1747 in the Gal4 activation domain. 
Transformants were selected on minimal Difco –Leu –Trp plates and further tested for lacZ 
expression by β-galactosidase assay using o-nitrophenyl β-D-galactopyranoside as substrate. (1) 
S. cerevisiae [pGAD/pGBD]. (2) S. cerevisiae [pGAD Rv1747/pGBD]. (3) S. cerevisiae 
[pGAD/pGBD PknF]. (4) S. cerevisiae [pGAD Rv1747/pGBD Rv1747]. (5) S. cerevisiae [pGAD 
Rv1747/pGBD PknF]. (6) S. cerevisiae [pGAD Rv1747 S47A/pGBD PknF]. (7) S. cerevisiae 
[pGAD Rv1747 S248A/pGBD PknF]. (8) S. cerevisiae [pGAD Rv1747/pGBD PknF K41A]. (9) 
S. cerevisiae [pGAD Rv1747/pGBD PknF T173A]. (10) S. cerevisiae [pGAD Rv1747/pGBD 
PknF T175A]. (11) S. cerevisiae [pGAD Rv1747/pGBD PknF T178A]. 
FIG. 6. Structure of the pThr binding site in FHA domains. The top panel shows the interactions 
of Ser85 and Arg70 from the N-terminal FHA domain (FHA1) of Saccharomyces cerevisae 
Rad53p checkpoint kinase (11). The lower panel shows a sequence overlap within the core FHA 
homology region between Rad53p FHA1 and the two FHA domains of M. tuberculosis Rv1747. 
Six of the most highly conserved residues are highlighted (Arg70 and Ser85 in red, Gly69, His88, 
Asn107 and Asn112 in blue - Rad53 numbering).  
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TABLE 1. Oligonucleotide primer pairs used for site directed mutagenesis of pknF and Rv1747. 
 
Gene  Mutation  Primer sequences 5'-3'
a 
pknF  K41→A  CGCCAGGACGCGCTCGCGGTACTGCGGGCCG 
CGGCCCGCAGTACCGCGAGCGCGTCCTGGCG 
pknF  T173→A  CCAAGCGGATTGGCCGCCACAAACATGACTGTGGGC 
GCCCACAGTCATGTTTGTGGCGGCCAATCCGCTTGG 
pknF  T175→A  CCAAGCGGATTGACCGCCGCAAACATGACTGTGGGC 
GCCCACAGTCATGTTTGCGGCGGTCAATCCGCTTGG 
pknF  T178→A  CCGCCACAAACATGGCTGTGGGCACCG 
CCGTGCCCACAGCCATGTTTGTGGCGG 
Rv1747  S47→A  CGCACACCCCCTGATCGCCCGGGCACACCTGCTGC 
GCAGCAGGTGTGCCCGGGCGATCAGGGGGTGTGCG 
Rv1747  S248→A  CCCGAGGTGTTGGCCGCACGTCACCACGCCACCC 
GGGTGGCGTGGTGACGTGCGGCCAACACCTCGGG 
 
aUnderlined bases indicate the change of an amino acid to alanine.  
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